Dr. Jorge A. Fortun, MD

Dr. Fortun practices at Bascom Palmer Eye Institute in Miami, Florida.

Dr. Fortun's NPI, 1184736464, was assigned on August 31, 2006. Dr. Fortun graduated from University Of Michigan Medical School in 2004. Dr. Fortun holds Florida license ME107110.

Dr. Fortun's primary practice is Bascom Palmer Eye Institute, at 900 NW 17th St, Miami, FL 33136 in Miami-Dade County. The practice phone is (239) 659-3937.

Dr. Fortun's primary practice is Bascom Palmer Eye Institute in Miami, Florida. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fortun practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Fortun's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Fortun is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Fortun's licenses on file in 3 states: Florida, Texas and Georgia.

Dmand AI lists age-related macular degeneration, dry eye, hypertensive retinopathy, inflammation of iris, laser destruction of retinal or choroid lesions, retinal detachment, retinal occlusion and secondary membranaous cataract surgery among the conditions Dr. Fortun treats.

CMS data shows 81,450 Medicare services from Dr. Fortun across 19 procedure codes in 2024, for 1,585 Medicare patients. Medicare paid $4,012,177 for them.

CMS counts 1,585 Medicare patients who saw Dr. Fortun in 2024. The largest group is 75 to 84, with 620 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fortun's median patient age at 74, with 56% women.

In 2024, Dr. Fortun wrote 261 Medicare Part D claims for 122 patients. 66% of them were for generic drugs. CMS names the drug for 194 of them, across 5 drugs with 11 or more claims each, at $5,220 in total drug cost. In 2023, CMS named 217 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Fortun for performance year 2024, reported as part of a group. Dr. Fortun accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fortun as offering telehealth.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 32 papers to Dr. Fortun, published from 2011 to 2024. 2022 was the busiest year, with 3. The most frequent topics are Vitrectomy, Retinal Detachment and Visual Acuity. Dr. Fortun has published most often in Clin Ophthalmol. Dr. Fortun's most frequent co-authors are Thomas A. Albini, MD, Luis J. Haddock, MD and William E. Smiddy, MD.

Dmand AI links Dr. Fortun to 4 clinical trials. Conditions studied include Eye Infections, Bacterial, Vitreoretinopathy, Proliferative and Eye Infections. Open Payments lists research payments to Dr. Fortun that name 1 trial.

CMS Open Payments shows 824 general payments to Dr. Fortun from 32 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 40% of the total. Apellis Pharmaceuticals, Inc. paid the most, $150,676. It also lists 9 research payments totaling $7,351 from 2017 to 2024, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Fortun, most recently CMS Stage 1 EHR in 2014.

Dr. Fortun graduated from University Of Michigan Medical School in 2004.

Dr. Fortun is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.